By: Ohad Schwartz


CoreBone developed and produces a bioactive coral-based bone graft – an efficient and natural alternative to current human and bovine bone derived grafts,that lead the global 4B$ orthopedic and dental markets.


Raised so far




Days to go
Minimum investment: $6,000
Stage:Round A
  • Campaign Highlights
  • Pitch
  • Team
  • Investors 4
  • Updates
  • The Deal
  • Documents
  • Disclosures

Campaign Highlights

Cutting Edge, Patent-Protected Technology

CoreBone has developed new innovative technology for the production of bio-active coral based grafts, which are a safe, high quality and cost effective alternative to the human and animal-derived bone grafts currently used in the orthopedic and dental fields.

The company has a registered patent in the USA, Europe, and Israel for the process of inserting bioactive minerals into corals while they grow - a unique procedure that encourages new bone growth around the coral implant, giving CoreBone a competitive and clinical advantage.


CoreBone is Breaking Into the Chinese Market

Over the past year, the company's CEO has visited China several times and met with leading medical companies. The Chinese market has a huge growth rate, with high potential and characterized by relatively low competition. In addition, coral-based products are of great interest and appreciation in China. CoreBone received excellent responses from leading dental and orthopedic hospitals, and as a result, has received several proposals for cooperation in China. The company is currently in advanced negotiations for the investment of a significant amount and the creation of cooperation with leading players in China. These contacts (TERM SHEET) embody an increase of 50% and more in the company's value for its investors.



An Innovative Solution for a Growing Market Worth $ 4 Billion

The dental and orthopedic market is estimated at $ 4 billion annually and is controlled by products originating from humans or animals. Most dental patients who undergo bone grafting procedures are not necessarily aware of the fact that the product implanted in their mouth is actually made of cow (bovine), pig (porcine) or even human bones. However, awareness to the use of safe natural products is rapidly increasing and the use of animal products is declining. CoreBone offers a safe  quality product, without the limitations of the human /animal derived products, at a competitive price, and is working hard to penetrate international markets and gain significant market share through its advanced products.


Multi-Year CE Approval for Marketing in Europe and Israel

The CoreBone product has regulatory approval in Europe and Israel for dental and orthopedic use, including CE certification for distribution in the European market, which has been renewed for an additional three years. In addition, the product is approved by the Israeli Ministry of Health and is currently being registered in Taiwan through a local distributor. The product was first marketed in Israel, France, Poland and Romania, for feedback and clinical follow-up. The company recently received product distribution requests in Spain, Italy, Australia, India, Argentina, Chile, China, Japan and others. The company scheduled to meet with distributors this March in Germany, at the world largest dental fare, and expect sales in these target markets to start later this year.

Invest Alongside Israel's Leading Medical Incubator

CoreBone, which has come a long way, is supported by the Israel Innovations Authority and has also received a significant investment from Trendlines, the leading bio-medical incubator in Israel, specializing in medical device and agro-tech investments. The company has raised about $ 2.5 million from the Israel Innovations Authority, Trendlines, entrepreneurs and private investors from Israel, the United States, England, Singapore and Poland, and completed a successful crowdfunding round through ExitValley a year ago, in which about $ 630,000 was raised.

Tremendous Clinical Success in the Dental Field and Initial Work in Orthopedics

Following the success in the dental field, with over 2000 successful transplants and excellent clinical data, Corbonne is expanding its distribution network and penetrating new markets. The company is currently starting a pilot project in the orthopedic-oncology department at Ichilov Medical Center, which will be used for clinical research, with the purpose of replacing the existing human-derived products for orthopedic transplants.


The idea

Need and Solution

Graft materials are used to create bone volume to stabilize and anchor implants. The bone replacement market, derived from the dental and orthopedic implants market, has been growing steadily for several reasons:

  • Population aging
  • The desire for aesthetic improvements and functional ability
  • The entry of huge countries such as China and India into this market

Today's graft materials originate in human bones and are the preferred clinical solution. However, this alternative contains several limitations:

  • Transmission of diseases
  • Rejection of the body
  • A procedure which is not accepted in many countries
  • The need to monitor the history of diseases of the "donor"

Graft materials derived from animals, especially cows and pigs, are common in the dental field. Due to the risk of transmitting resistant viruses such as mad cow, these implants undergo a high heat treatment of about c1000°, after which they lose their biological ability and become a ceramic substance that does not remodels (replaced by new bone as it grow).

In the market, there are also graft materials made from synthetic materials, but they are of low strength and tend to dissolve in the body at a faster rate than the bone building itself. These are often considered the least favored solution.

For these reasons, there is a strong need for a strong and effective product at a reasonable price, with properties similar to bone properties, which will enable maintaining bone volume through an efficient transition process. CoreBone answers this need with a bone-like product in terms of structure and composition, but not produced from the bone of a mammal, with all the risks included.



The Technology

CoreBone grafts are made from corals that are grown (cultured) in a closed, monitored laboratory environment (coral farm). Patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of selected coral types during their growth process, utilizing their bone-like qualities and adding bioactivity for accelerated bone healing and better bone connectivity. As a result, the CoreBone graft material offers the same bone-like qualities as organic material (human-derived) without the associated biological risks.



This is a natural alternative to products derived from human or animal origin, with bioactive components that even encourage natural bone growth.


CoreBone in the Media





The Benefits of CoreBone

CoreBone's product, innovation, and uniqueness have been received very well so far by field experts and opinion leaders. The common opinion is that the CoreBone product has a variety of unique advantages over existing solutions:

  • The product is produced from corals instead of human or animal bones- and therefore does not undergo virus preventing heat treatment that damages the ability to resorb - the natural ability of the bone to grow again.
  • CoreBone's product is a natural and safe alternative to human or animal substances.
  • CoreBone's product is preferable for reasons of ethics, vegetarianism / veganism, and religion (Jews, Muslims, Hindus) - growing market segments.
  • CoreBone's product price is attractive - 40% cheaper than leading products.




Development and Vision

CoreBone is the story of two worlds that combine in perfect synergy, behind which stands a group of wonderful staff members, each of whom is a world renowned expert in their field. The team members successfully combine their knowledge and experience in the worlds of bone research and marine biology to create a breakthrough product that revolutionizes a market with great potential.

Led by its team of experts, the company has developed a coral-based bone replacement for cases of injury, disease and transplant support, which is an effective, safe and eco-friendly alternative to the leading products produced today by human or animal bones for the risks involved.

In 2005, the Kyoto Protocol on Global Warming was signed, stating that the coral reefs are becoming extinct at a high rate and are expected to disappear by half a century. The convention stated that it is forbidden to harvest and trade corals. Following the convention, the CoreBone team began exploring the use of coral reefs. The team was greatly strengthened by Prof. Yitzhak Binderman, a world expert in mineralization and biology of bones, who was formerly an advisor to INTERPORE, which developed the first coral bone substitute.

CoreBone's idea of growing coral for this purpose, in a closed system while controlling the quality of water and corals, has been combined with the knowledge and experience of bio-activation - improving biological abilities and bone growth encouragement - a topic that Prof. Binderman has dealt with in recent years. The project was joined by Assaf Shaham, who has been involved in coral farming at Moshav Ein Yahav in the Arava. This is how CoreBone - the only company currently growing coral as a medical product designed for transplantation - was established.

CoreBone launched its products in the dental market in 2017 at the IDS exhibition in Germany, and from the beginning its unique solution has received much attention. The company began marketing its products in Israel and Poland. Initially, since the beginning of marketing, the Company focused on collecting user opinions and clinical data. These data were recently publicized in a clinical catalog published by the company, which includes a follow-up of over a year. The opinions we received were excellent and parallel to our product for the world's leading product - which originated from a cow, is not absorbed in the body (a requirement of doctors in many cases and basic conditions for the use of orthopedics).

Prof. Haim Tal, head of the transplant Department at Tel Aviv University and former head of the School of Dental Medicine, joined the company as a clinical and scientific consultant.

Today, the opinions we have gathered, the clinical data and the marketing material enable us to support the distributors in introducing a new product into the market, and we are prepared to expand marketing and distribution.

The company's goal and vision are to make CoreBone products the market leaders, both in dental use and in the orthopedic field, and continue to develop additional unique products for these markets.



Business Model

CoreBone's business model consists of three distinct and defined stages:

The first stage – product sales

CoreBone is currently marketing its products in the dental field in Israel, Poland, Romania and France, as well as online product adoption by users, research and clinical data collection are essential to this stage. The company plans in 2019 to sign an investment agreement in China to penetrate this major market.

The second stage - collaborations with dental implant companies

With the expansion of distribution networks, adoption of the product by users, creation of Traction and gathering clinical database - CorBonne plans to expand its distribution system by creating strategic partnerships with equipment companies and medical equipment companies.

The third stage – penetrating the orthopedic market

CoreBone holds a license for distributing its products to the orthopedic market in Europe and Israel. At the same time, this market is more institutionalized than the dental market and is controlled by global companies. In order to insert a new product into the orthopedic market, clinical research and collaboration with leading orthopedic agents are necessary.

CoreBone has recently launched a pilot project to be used for clinical research in the Orthopedic / Oncology Department of the Sourasky Medical Center. A successful clinical trial will significantly advance the company's orthopedic product towards penetrating this market.

CoreBone has already signed confidentiality agreements with several leading global orthopedic companies.



The market

The market for bone substitutes (human bone, animal bone and synthetic) is expected to reach $ 4.33 billion in 2022.

Orthopedic Market

• This market is estimated at about $ 3.2 billion a year. While the annual growth rate of the orthopedic market in the US is 4.5%, the CAGR in South East Asia is 11.6%!

• In the orthopedic sector, the US and Europe each control about 40% of the world market, but are expected to shrink to about a third with the growth of new markets - China and India.

The orthopedic bone replacements market has a number of growth engines:

  • Population aging due to the extension of life expectancy
  • Increase in disposable income per person in emerging markets
  • Market growth in Southeast Asia

Dental Market

  • The growth rate of the global dental market is about 10% per year.
  • In the dental field, Europe accounts for about 45% of the market size and the US 25%
  • Countries leading the market in Europe are: Germany, Italy, Spain and France.
  • England is in the back, but its share will increase following a policy change (transition to private market treatments).
  • China - growing twice as fast as Europe

Chart of the Dental Market by Country:

Go To Market

Entering the Chinese Market

Following a thorough study of the Chinese market and a series of visits and meetings with leading players in the Chinese market, Corbonne received proposals for cooperation and investment in the company, including the establishment of a joint venture for the commercializing of the CoreBone technologology in this huge market, which is characterized by high growth rate, apritiation of natural materials / corals and high profitability.

* CoreBone is currently in advanced negotiations with Chinese companies and signing agreements is expected to happen in the coming months.


The exit strategy

Currently, almost all orthopedic and dental implant companies are marketing bone replacements for situations requiring implantation. This affects the company's marketing strategy, as well as its exit strategy.

The implants and bone replacements market is characterized by substantial activity of mergers and acquisitions. Unlike in the past, the acquired company is required to present clinical evidence, along with regulatory approvals, and a rate of increase in sales.

CoreBone has proven to date that it can develop an innovative, structured and efficient product that meets market requirements, as well as all regulatory approvals for Europe and Israel, and is soon expected to have operation approval in the US market as well. These, and more, make CoreBone an attractive target for acquisition by leading global companies.

The current round is intended to strengthen the company's position in the market and increase sales rate, as well as collection of large-scale clinical data for medical publications and the initiation of product registration in the US (FDA 510K).

In the dental market alone, some 50 M&A transactions have been observed in recent years alone, including a significant number of bone substitute manufacturers, as detailed in the table above. These are acquisitions by giant companies that invested hundreds of millions of dollars in such acquisitions.

Use of proceeds

The purpose of the fundraising is to enable the company to finance its operations before completing the financing round with the potential Chinese partners, and to intensify the investment so that the company will be able to operate fully.


Ohad Schwartz
CEO and Marketing Manager, Co-Founder
Ohad is an experienced entrepreneur and manager, together with Prof. Itzhak Binderman, and has run the company since its founding. Prior to that, Ohad ran several start-up companies, including VAICA, which developed a system for monitoring the use of drugs designed for third-age and chronically ill patients. In addition, Ohad co-founded ASPEC AI, which developed mobile MRI systems for use in industry (food, medicine) and agriculture. Prior to this, Ohad served as VP of International Business Development and Marketing at several leading companies such as Tami4, Finish / Teknion, etc. He has a BA in Economics and Management and an MBA from Tel Aviv University.

Prof. Itzhak Binderman
DMD, Former CTO, Co-Founder
Professor Yitzhak Binderman, a world renowned scientist in the field of mineralization and biology of bone, who initiated in collaboration CoreBone with Ohad. Professor Binderman served as Chief Technology Officer (CTO) of CoreBone until the beginning of 2017, and has since served as a consultant to the company. Prof. Binderman has been a researcher at the Weizmann Institute of Science, founded and managed the bone laboratory at Ichilov Hospital and managed the dental department at the hospital for 25 years, and was a visiting scientist at the NIH, And has served as a medical consultant to ORTHOVITA, which has developed PRO-OSTEON, which has been a leading bone substitute for many years, and currently serves as a lecturer at Tel Aviv University‘s School of Dental Medicine and Biomedical Engineering.

  • Founder
Assaf Shaham
Coral Expert and Coral Farm Manager
Born in Moshav Ein Yahav, a member of the founding generation, Pepper Growers. About a decade ago, with the publication of the Kyoto Protocol and the ban on coral trade, Assaf initiated the establishment of an innovative coral farming farm as an alternative to traditional agriculture in the Arava. Assaf has experience in setting up complex lighting systems and even established the lighting system at Yad Vashem. Over the past decade, Asaf has acquired extensive knowledge and experience in the field of coral growth and is now considered a renowned expert. Since the founding of CoreBone Assaf has been engaged in coral development and production for the medical field. Today, the coral farm under his leadership is considered a leader in its field.

Prof. Haim Tal
Scientific Advisor
Head of the Department of Periodontology and Oral Implants and former dean of the Tel Aviv University School of Dental Medicine.

  • Advisor

Investors 4

Anonymous Investor
Anonymous Investor
Anonymous Investor
Anonymous Investor


Currently there are no updates in this pitch

The Deal



Follow us